Repeated low-dose administration of a MAGL inhibitor retained its pain-relieving and stomach-protecting effects without causing CB1 receptor tolerance or cannabinoid dependence, unlike high doses which caused both.
Read this if you are interested in how boosting the body's natural cannabinoids could treat pain without the downsides of THC.
Low doses maintained therapeutic effects while high doses caused tolerance and dependence
What the researchers found
The MAGL inhibitor JZL184 blocks the enzyme that breaks down the endocannabinoid 2-AG, boosting natural cannabinoid signaling. When given at high doses (16+ mg/kg daily for 6 days), it caused CB1 receptor downregulation, desensitization, antinociceptive tolerance, cross-tolerance to THC, and cannabinoid dependence.
However, at low doses (8 mg/kg or less), JZL184 maintained its pain-relieving effects in a neuropathic pain model and stomach-protective effects against NSAID damage, with no CB1 receptor downregulation, no tolerance, no cross-tolerance to THC, and no dependence. This demonstrates that partial MAGL inhibition can provide therapeutic benefits without the drawbacks of full inhibition.
Why it matters
This study solved a key problem in endocannabinoid drug development. Full MAGL inhibition produces tolerance just like chronic THC, but partial inhibition maintains the benefits. This provides a roadmap for developing MAGL inhibitors as medicines: keep the dose low enough for partial inhibition.
The numbers in context
High dose (16+ mg/kg): CB1 downregulation, desensitization, tolerance, cross-tolerance to THC, dependence. Low dose (8 mg/kg or less): no downregulation, no desensitization, maintained pain relief, maintained gastroprotection, no THC cross-tolerance, no dependence.
How the study worked
Mouse studies using repeated daily JZL184 at multiple doses. CB1 receptor density measured by [3H]SR141716A binding. CB1 function measured by CP55,940-stimulated GTPgammaS binding. Behavioral assessments: neuropathic pain (chronic constriction injury), gastroprotection (NSAID-induced hemorrhage), THC cross-tolerance, rimonabant-precipitated withdrawal.
What this study cannot tell us
Mouse studies may not translate to humans. Only one MAGL inhibitor was tested. The neuropathic pain model and gastroprotection model are specific paradigms. The 6-day treatment period is relatively short. Whether partial MAGL inhibition maintains efficacy over months or years is unknown.
How to read the evidence
Comprehensive preclinical study with multiple converging measures; moderate evidence for a therapeutic window.
When this study was published
Published in 2013. MAGL inhibitor drug development has continued based on this partial-inhibition principle.
The bigger picture
This study established a crucial therapeutic principle: the dose that produces tolerance is higher than the dose needed for therapeutic effects. By staying below the tolerance threshold, MAGL inhibitors could provide sustained pain and inflammation relief through the body's own endocannabinoid system without the problems of chronic THC use.
Questions still open
- Where is the dose threshold between therapeutic effect and tolerance in humans? Would low-dose MAGL inhibitors be effective for chronic pain conditions? Could MAGL inhibitors replace NSAIDs for patients at risk of stomach ulcers?
Common questions
What is MAGL and why does inhibiting it matter?
Could this lead to better pain medications?
Read the original research
Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects.
The Journal of pharmacology and experimental therapeutics, 345(3), 492-501
Citation
Kinsey, Steven G; Wise, Laura E; Ramesh, Divya; Abdullah, Rehab; Selley, Dana E; Cravatt, Benjamin F; Lichtman, Aron H. (2013). Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects.. The Journal of pharmacology and experimental therapeutics, 345(3), 492-501. https://doi.org/10.1124/jpet.112.201426
Explore the wider topic
- How THC Affects Your Amygdala: The Brain's Threat Detector and Cannabis
- The Anandamide Connection: Your Body's Natural Bliss Molecule
- How Long for Cannabinoid Receptors to Return to Normal
- Cannabis and the Developing Brain: What Every Teenager (and Parent) Should Know
- Why Can't I Enjoy Anything Without Weed? The Science Behind It
- Dopamine Recovery After Quitting Weed: What the Science Says
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- Your Nervous System After Quitting Weed: Fight or Flight
- Using Weed Under 18: What It Does to Your Developing Brain
- What THC Does to Your Brain: Why Withdrawal Happens
- THC and Your Prefrontal Cortex: What Cannabis Does to Your Decision-Making Brain
- Weed, Cortisol, and Stress: What Cannabis Does to Your Stress Hormones
- Weed and Memory: What the Science Says About THC and Your Hippocampus
- Weed and Motivation: Is Amotivational Syndrome Real?
- Weed and Your Nervous System: What THC Actually Does to Your Brain and Body
- How Weed Rewires Your Reward System (And How to Reset It)
- Cannabis and Arthritis: What the Research Actually Shows